{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(1)"],"submitter":["Berlinger MS"],"pubmed_abstract":["Sepsis, a condition characterized by immune dysregulation, is the leading cause of in-hospital mortality and requires rapid treatment. Assessing immune dysregulation has been challenging. The IntelliSep Index (ISI), a novel biomarker which leverages microfluidic deformability cytometry to assess immune activation, has been evaluated as a test for Emergency Department use but it is unclear how the signal evolves as patient condition evolves. In a 47-patient cohort with hospital stays ≤ 14 days, ISI provided a good indicator of disease progression by blinded physician review. ISI trends correlated with clinical improvement over time. During the first 12 h following presentation, ISI was unaffected by antibiotic treatment initiated in the emergency department (ED). After this period however, "],"journal":["Scientific reports"],"pagination":["30501"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12368155"],"repository":["biostudies-literature"],"pubmed_title":["Temporal trends of a cellular host response test for sepsis and a comparison with selected biomarkers of inflammation and infection."],"pmcid":["PMC12368155"],"pubmed_authors":["Ochsner SP","O'Neal HR","Daigle J","Avornu G","Walker JE","Cembellin-Kao A","Maia Q","Sorrells M","Quiriarte H","Shah AM","Thomas CB","Berlinger MS","Rothman R","Sheybani R","Tse HTK","Jagneaux T","Scoggins R","King C","Fenstermacher K","Kurien EJ","Yonamine C","Spielmann G","Robertson D","Hager DN","Kim Y","Obrebski M"],"additional_accession":[]},"is_claimable":false,"name":"Temporal trends of a cellular host response test for sepsis and a comparison with selected biomarkers of inflammation and infection.","description":"Sepsis, a condition characterized by immune dysregulation, is the leading cause of in-hospital mortality and requires rapid treatment. Assessing immune dysregulation has been challenging. The IntelliSep Index (ISI), a novel biomarker which leverages microfluidic deformability cytometry to assess immune activation, has been evaluated as a test for Emergency Department use but it is unclear how the signal evolves as patient condition evolves. In a 47-patient cohort with hospital stays ≤ 14 days, ISI provided a good indicator of disease progression by blinded physician review. ISI trends correlated with clinical improvement over time. During the first 12 h following presentation, ISI was unaffected by antibiotic treatment initiated in the emergency department (ED). After this period however, ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-05T19:02:23.789Z","creation":"2026-04-07T21:50:57.419Z"},"accession":"S-EPMC12368155","cross_references":{"pubmed":["40836052"],"doi":["10.1038/s41598-025-14860-w"]}}